Zogenix’s pain is GW Pharma’s gain
A regulatory misstep puts Zogenix even further behind its epilepsy rival GW Pharma, which in turn is waiting for data that could give it another boost.
Supernus struggles to gain attention
A phase III failure will do nothing to help Supernus’s SPN-812 compete against generic ADHD drugs.
Readouts approach for biggest Huntington’s hopes
Upcoming data from Roche/Ionis and Wave Life Sciences will be an important test of potentially disease-modifying candidates.
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
A successful Mylan challenge would see generic entry within two years – though Biogen has fought off copycats before.
Upcoming events – Roche aims to change autism and Ocular awaits pivotal results
Roche awaits a high-risk, high-reward readout in autism, while for Ocular Therapeutix placebo ought to be easier to beat than active control.
Eisai and Biogen throw good money after bad
The companies’ decision to start a 1,500-patient Alzheimer’s disease study defies logic.
No, aducanumab is not an Alzheimer’s drug either
Failure at a futility analysis blows a big hole in Biogen's pipeline. Can the company buy in growth or will its valuation sink enough for it to become a target?
Probiodrug wins a market cap-sized grant for Alzheimer’s trial
Probiodrug grabs $15m, but it will need more to fund phase IIb development of its Alzheimer’s candidate, PQ912.
Lundbeck needs deals, but what can it afford?
With few pipeline catalysts this year the pressure is growing on Lundbeck's new chief executive, Deborah Dunsire, to deliver a deal. But the company only has $5bn to…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.